{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T04:59:37Z","timestamp":1793681977731,"version":"4.5.1"},"reference-count":70,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>New therapies are urgently needed for patients with osteosarcoma (OS). STAT3 and CD47 are potential therapeutic target in OS. Here we investigated the therapeutic activity of the orally bioavailable STAT3 inhibitor, WP1066, and anti-CD47 antibody using OS mouse models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Cytotoxic effect of WP1066 against OS cell lines and its immunomodulatory effects were evaluated\n                      <jats:italic>in vitro<\/jats:italic>\n                      . Experimental metastasis and orthotopic syngeneic mouse models were used to investigate the therapeutic efficacy of WP1066 and anti-CD47 antibody. Further flow cytometric analysis was performed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      STAT3 was constitutively activated in multiple human and mouse OS cell lines. WP1066 suppressed STAT3 activation and induced apoptosis. WP1066 reduced the viability and proliferation of MDSCs and increased the expression level of MHC-II, and CD80 in macrophages. We demonstrated that WP1066 monotherapy prolonged the survival of mice with OS lung metastasis using an experimental metastasis and an orthotopic model. The therapeutic effect was significantly increased when WP1066 was combined with anti-CD47. This was associated with increased frequency of activated CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells, NK cells and macrophages in the lungs and LDLNs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our preclinical studies support further investigation of targeting STAT3 and CD47 as novel immunotherapeutic approach against OS lung metastasis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1608375","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T01:22:13Z","timestamp":1748913733000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["STAT3 inhibition in combination with CD47 blockade inhibits osteosarcoma lung metastasis"],"prefix":"10.3389","volume":"16","author":[{"given":"Pradeep","family":"Shrestha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rejeena","family":"Shrestha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafal","family":"Zielinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waldemar","family":"Priebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenie S.","family":"Kleinerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2103423","article-title":"New horizons in the treatment of osteosarcoma","volume":"385","author":"Meltzer","year":"2021","journal-title":"New Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41572-022-00409-y","article-title":"Osteosarcoma","volume":"8","author":"Beird","year":"2022","journal-title":"Nat Rev Dis Primers"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30270-4","article-title":"Maximum benefit of chemotherapy for osteosarcoma achieved\u2014What are the next steps","volume":"17","author":"Kleinerman","year":"2016","journal-title":"Lancet Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3818","article-title":"Revisiting STAT3 signalling in cancer: new and unexpected biological functions","volume":"14","author":"Yu","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/s0092-8674(00)81959-5","article-title":"Stat3 as an oncogene","volume":"98","author":"Bromberg","year":"1999","journal-title":"Cell"},{"key":"B6","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41568-018-0090-8","article-title":"Therapeutically exploiting STAT3 activity in cancer \u2014 Using tissue repair as a road map","volume":"19","author":"Huynh","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.12974","article-title":"STAT3 and its targeting inhibitors in osteosarcoma","volume":"54","author":"Liu","year":"2020","journal-title":"Cell Prolif"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-9-81","article-title":"Characterization of STAT3 activation and expression in canine and human osteosarcoma","volume":"9","author":"Fossey","year":"2009","journal-title":"BMC Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2017.270","article-title":"Toosendanin demonstrates promising antitumor efficacy in osteosarcoma by targeting STAT3","volume":"36","author":"Zhang","year":"2017","journal-title":"Oncogene"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.acthis.2010.03.002","article-title":"Clinical value of signal transducers and activators of transcription 3 (STAT3) gene expression in human osteosarcoma","volume":"113","author":"Wang","year":"2011","journal-title":"Acta Histochem"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2012.03.039","article-title":"S1PR1-STAT3 signaling is crucial for myeloid cell colonization at future metastatic sites","volume":"21","author":"Deng","year":"2012","journal-title":"Cancer Cell"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-19-2013","article-title":"IL6\/STAT3 signaling orchestrates premetastatic niche formation and immunosuppressive traits in lung","volume":"80","author":"Jing","year":"2020","journal-title":"Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-2770","article-title":"STAT3 establishes an immunosuppressive microenvironment during the early stages of breast carcinogenesis to promote tumor growth and metastasis","volume":"76","author":"Jones","year":"2016","journal-title":"Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nri1995","article-title":"Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment","volume":"7","author":"Yu","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/nrc2734","article-title":"STATs in cancer inflammation and immunity: A leading role for STAT3","volume":"9","author":"Yu","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2011.543129","article-title":"Mifamurtide for the treatment of nonmetastatic osteosarcoma","volume":"12","author":"Ando","year":"2011","journal-title":"Expert Opin Pharmacother"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.14.0095","article-title":"Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival-a report from the children\u2019s oncology group","volume":"26","author":"Meyers","year":"2008","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-199504000-00001","article-title":"Efficacy of liposomal muramyl tripeptide (CGP 19835a) in the treatment of relapsed osteosarcoma","volume":"18","author":"Kleinerman","year":"1995","journal-title":"Am J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-04843-7_17","article-title":"Muramyl tripeptide-phosphatidyl ethanolamine encapsulated in liposomes (L-MPT-PE) in the treatment of osteosarcoma","author":"Meyers","year":"2014","journal-title":"Curr Adv Osteosarcoma"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1747340","DOI":"10.1080\/2162402X.2020.1747340","article-title":"Tumor-associated macrophages and macrophage-related immune checkpoint expression in sarcomas","volume":"9","author":"Dancsok","year":"2020","journal-title":"Oncoimmunology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"6308","DOI":"10.1038\/s41467-022-34064-4","article-title":"Metabolic control of CD47 expression through lat2-mediated amino acid uptake promotes tumor immune evasion","volume":"13","author":"Wang","year":"2022","journal-title":"Nat Commun"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00519-8","article-title":"Advancing therapy for osteosarcoma","volume":"18","author":"Gill","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e004589","DOI":"10.1136\/jitc-2022-004589","article-title":"CD47\/SIRP\u03b1 Axis: bridging innate and adaptive immunity","volume":"10","author":"van Duijn","year":"2022","journal-title":"J ImmunoTher Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20200839","article-title":"The SIRP\u03b1-CD47 immune checkpoint in nk cells","volume":"218","author":"Deuse","year":"2021","journal-title":"J Exp Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.Cir-18-0367","article-title":"Natural killer cell recruitment and activation are regulated by CD47 expression in the tumor microenvironment","volume":"7","author":"Nath","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1038\/nm.3931","article-title":"CD47 blockade triggers T cell\u2013mediated destruction of immunogenic tumors","volume":"21","author":"Liu","year":"2015","journal-title":"Nat Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-14-2520","article-title":"Molecular pathways: activating T cells after cancer cell phagocytosis from blockade of cd47 \u201cDon\u2019t eat me\u201d Signals","volume":"21","author":"McCracken","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","first-page":"CNS87","DOI":"10.2217\/cns-2022-0005","article-title":"A first-in-human phase I trial of the oral P-STAT3 inhibitor WP1066 in patients with recurrent Malignant glioma","volume":"11","author":"Groot","year":"2022","journal-title":"CNS Oncol"},{"key":"B30","article-title":"The preclinical pharmacology of WP1066, a potent small molecule inhibitor of the JAK2\/STAT3 pathway","volume":"66","author":"Madden","year":"2006","journal-title":"Cancer Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"4540","DOI":"10.1158\/1538-7445.AM2015-4540","article-title":"Development of orally bioavailable formulation of WP1066 and its evaluation in vivo","volume":"75","author":"Zielinski","year":"2015","journal-title":"AACR"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-1243","article-title":"A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients","volume":"67","author":"Hussain","year":"2007","journal-title":"Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-1693","article-title":"Intratumoral mediated immunosuppression is prognostic in genetically engineered murine models of glioma and correlates to immunotherapeutic responses","volume":"16","author":"Kong","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-008-0618-y","article-title":"A Novel Phosphorylated STAT3 Inhibitor Enhances T Cell Cytotoxicity against Melanoma through Inhibition of Regulatory T Cells","volume":"58","author":"Kong","year":"2009","journal-title":"Cancer Immunol Immunother: CII"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14174310","article-title":"Pramlintide: A novel therapeutic approach for osteosarcoma through metabolic reprogramming","volume":"14","author":"Yang","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.99791","article-title":"Il-6 and CXCL8 mediate osteosarcoma-lung interactions critical to metastasis","volume":"3","author":"Gross","year":"2018","journal-title":"JCI Insight"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-0436.1988.tb00090.x","article-title":"Establishment and characterization of osteogenic cell lines from a spontaneous murine osteosarcoma","volume":"39","author":"Schmidt","year":"1988","journal-title":"Differentiation"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0313","article-title":"Corruption of the fas pathway delays the pulmonary clearance of murine osteosarcoma cells, enhances their metastatic potential, and reduces the effect of aerosol gemcitabine","volume":"13","author":"Gordon","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19980504)76:3<418::AID-IJC21>3.0.CO;2-5","article-title":"Establishment and characterization of a murine osteosarcoma cell line (Lm8) with high metastatic potential to the lung","volume":"76","author":"Asai","year":"1998","journal-title":"Int J Cancer"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s10585-007-9133-3","article-title":"Inhibition of the CXCR4\/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases","volume":"25","author":"Kim","year":"2008","journal-title":"Clin Exp Metastasis"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00013","article-title":"Understanding and modeling metastasis biology to improve therapeutic strategies for combating osteosarcoma progression","volume":"10","author":"Fan","year":"2020","journal-title":"Front Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-4092","article-title":"Radiation with stat3 blockade triggers dendritic cell\u2013T cell interactions in the glioma microenvironment and therapeutic efficacy","volume":"26","author":"Ott","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B43","doi-asserted-by":"publisher","first-page":"5759","DOI":"10.1158\/1078-0432.CCR-08-0377","article-title":"A novel inhibitor of STAT3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells","volume":"14","author":"Kong","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1121623109","article-title":"The CD47-signal regulatory protein alpha (Sirpa) interaction is a therapeutic target for human solid tumors","volume":"109","author":"Willingham","year":"2012","journal-title":"Proc. Natl. Acad. Sci. (PNAS)"},{"key":"B45","doi-asserted-by":"publisher","first-page":"e003246","DOI":"10.1136\/jitc-2021-003246","article-title":"High potency sting agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege","volume":"9","author":"Ager","year":"2021","journal-title":"J ImmunoTher Cancer"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41563-018-0099-0","article-title":"Local immunomodulation with fas ligand-engineered biomaterials achieves allogeneic islet graft acceptance","volume":"17","author":"Headen","year":"2018","journal-title":"Nat Mater"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3965","article-title":"CD47 blockade as another immune checkpoint therapy for cancer","volume":"21","author":"Vonderheide","year":"2015","journal-title":"Nat Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"e004384","DOI":"10.1136\/jitc-2021-004384","article-title":"STAT3 inhibitor napabucasin abrogates mdsc immunosuppressive capacity and prolongs survival of melanoma-bearing mice","volume":"10","author":"Bitsch","year":"2022","journal-title":"J ImmunoTher Cancer"},{"key":"B49","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41420-023-01575-y","article-title":"Selective activation of STAT3 and STAT5 dictates the fate of myeloid progenitor cells","volume":"9","author":"Zhang","year":"2023","journal-title":"Cell Death Discov"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1172\/JCI59643","article-title":"Macrophage plasticity and polarization: in vivo veritas","volume":"122","author":"Sica","year":"2012","journal-title":"J Clin Invest"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.12556","article-title":"Improving the efficacy of osteosarcoma therapy: combining drugs that turn cancer cell \u2018Don\u2019t eat me\u2019signals off and \u2018Eat me\u2019signals on","volume":"13","author":"Mohanty","year":"2019","journal-title":"Mol Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(16)30214-5","article-title":"Comparison of mapie versus map in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (Euramos-1): an open-label, international, randomised controlled trial","volume":"17","author":"Marina","year":"2016","journal-title":"Lancet Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.65.5381","article-title":"Outcome of patients with recurrent osteosarcoma enrolled in seven phase ii trials through children\u2019s cancer group, pediatric oncology group, and children\u2019s oncology group: learning from the past to move forward","volume":"34","author":"Lagmay","year":"2016","journal-title":"J Clin Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (Sarc028): A multicentre, two-cohort, single-arm, open-label, phase 2 trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"e001772","DOI":"10.1136\/jitc-2020-001772","article-title":"Pathways of immune exclusion in metastatic osteosarcoma are associated with inferior patient outcomes","volume":"9","author":"Ligon","year":"2021","journal-title":"J ImmunoTher Cancer"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2047","article-title":"Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: A rationale for treatment with macrophage activating agents","volume":"17","author":"Buddingh","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-014-2005-y","article-title":"Inhibition of macrophage polarization prohibits growth of human osteosarcoma","volume":"35","author":"Xiao","year":"2014","journal-title":"Tumor Biol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01625-x","article-title":"Anti-gd2 synergizes with cd47 blockade to mediate tumor eradication","volume":"28","author":"Theruvath","year":"2022","journal-title":"Nat Med"},{"key":"B59","doi-asserted-by":"publisher","first-page":"e28975","DOI":"10.4161\/jkst.28975","article-title":"STAT3 and epithelial-mesenchymal transitions in carcinomas","volume":"3","author":"Wendt","year":"2014","journal-title":"Jakstat"},{"key":"B60","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.tips.2015.10.001","article-title":"Feedback activation of STAT3 as a cancer drug-resistance mechanism","volume":"37","author":"Zhao","year":"2016","journal-title":"Trends Pharmacol Sci"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605691","article-title":"STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma","volume":"102","author":"Horiguchi","year":"2010","journal-title":"Br J Cancer"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3892\/or.2017.5902","article-title":"STAT3 inhibition by WP1066 suppresses the growth and invasiveness of bladder cancer cells","volume":"38","author":"Tsujita","year":"2017","journal-title":"Oncol Rep"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-07-0593","article-title":"WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells","volume":"67","author":"Ferrajoli","year":"2007","journal-title":"Cancer Res"},{"key":"B64","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.cell.2010.07.044","article-title":"Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-hodgkin lymphoma","volume":"142","author":"Chao","year":"2010","journal-title":"Cell"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3001375","article-title":"Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47","volume":"2","author":"Chao","year":"2010","journal-title":"Sci Trans Med"},{"key":"B66","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41419-018-1285-3","article-title":"Nanoparticle enhanced mri can monitor macrophage response to CD47 mab immunotherapy in osteosarcoma","volume":"10","author":"Mohanty","year":"2019","journal-title":"Cell Death Dis"},{"key":"B67","unstructured":"WP1066 in Children with Refractory and Progressive or Recurrent Malignant Brain Tumors\n          \n          \n          \n          2023"},{"key":"B68","unstructured":"Fda Grants 3 Rare Pediatric Disease Designations to STAT3 Inhibitor WP1066\n          \n          \n          \n          2021"},{"key":"B69","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40364-023-00456-x","article-title":"The landscape overview of CD47-based immunotherapy for hematological Malignancies","volume":"11","author":"Yang","year":"2023","journal-title":"Biomarker Res"},{"key":"B70","unstructured":"Fda Halts Clinical Studies of Magrolimab in Aml, Mds\n          \n          \n            \n              Serani\n              S\n            \n          \n          \n          2024"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1608375\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T01:22:15Z","timestamp":1748913735000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1608375\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,3]]},"references-count":70,"alternative-id":["10.3389\/fimmu.2025.1608375"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1608375","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,3]]},"article-number":"1608375"}}